Cognition Therapeutics President and CEO Lisa Ricciardi presented an overview of the Company’s clinical programs, including the successful Phase 2 ‘SHINE’ study of CT1812 in mild-to-moderate Alzheimer’s disease, and the Phase 2 ‘SHIMMER’ study in dementia with Lewy bodies. To listen to the archive, please click the link below.
Location
Virtual